High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers
| Autor: | Carolina Ponce, Verónica Fabiano, Constanza Pérez de la Puente, Maria Victoria Costanzo, Mora Amat, Federico Coló, Manglio Rizzo, Chacon Reinaldo, Pablo Mandó, Carlos Martin Loza, Jorge Nadal, Maria Teresa Pombo, Adrian Nervo, M Maino, Jose Loza |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Pathology Concordance Lymphatic metastasis Estrogen receptor 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Progesterone receptor medicine Ki-67 antigen skin and connective tissue diseases Receptor biology business.industry Odds ratio medicine.disease Phenotype 030104 developmental biology 030220 oncology & carcinogenesis Ki-67 biology.protein Original Article Breast neoplasms NODAL business |
| Zdroj: | Journal of Breast Cancer |
| ISSN: | 2092-9900 1738-6756 |
| Popis: | Purpose Several studies have shown that estrogen receptor (ER) and progesterone receptor (PR) expression and human epidermal growth factor receptor 2 (HER2) expression may vary during tumoral progression. We aimed to describe and compare ER, PR, and HER2 expressions in primary breast tumors and synchronic axillary nodal metastases, and evaluate phenotypic correlations between them. Methods Patients were identified prospectively through surgical procedures between September 2013 and July 2016. The status of ER, PR, HER2, and Ki-67 were pathologically analyzed in breast cancers and axillary nodal metastases; these patients were classified based on the breast cancer phenotypes into five subgroups. Results Synchronic axillary nodal metastases were observed in 127 patients. In breast cancers and nodal metastases, correlation analyses of ER, PR, and Ki-67 expression showed a statistical dependence and concordance between these samples was unambiguously demonstrated through Bland-Altman plots for each determination. Primary breast tumors were classified as follows: luminal A, 41.6%; luminal B, 40.0%; luminal B/HER2, 9.6%; HER2, 2.4%; triple negative, 6.4%. Alterations in phenotype were observed in 28% of patients. The most frequent phenotypic alteration was from luminal B to A (36.4%). Ten cases (30.3%) showed alterations with therapeutic implications; six gained HER2 overexpression, and four, hormonal receptor (HR) expression. A moderate strength of agreement (Cohen's κ coefficient, 0.59; 95% confidence interval, 0.48–0.71) was observed. In multivariate analyses, high histologic grade (odds ratio [OR], 2.79; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|